The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index; none of the 19 sources its claims cite is checked for support yet.
Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons
Open accessAbstract
Mitochondrial dysfunction is implicated in the pathophysiology of Parkinson′s disease (PD), a common age-associated neurodegenerative disease characterized by intraneuronal inclusions (Lewy bodies) and progressive degeneration of the nigrostriatal dopamine (DA) system. It has recently been demonstrated that midbrain DA neurons of PD patients and elderly humans contain high levels of somatic mtDNA mutations, which may impair respiratory chain function. However, clinical studies have not established whether the respiratory chain deficiency is a primary abnormality leading to inclusion formation and DA neuron death, or whether generalized metabolic abnormalities within the degenerating DA neurons cause secondary damage to mitochondria. We have used a reverse genetic approach to investigate this question and created conditional knockout mice (termed MitoPark mice), with disruption of the gene for mitochondrial transcription factor A ( Tfam ) in DA neurons. The knockout mice have reduced mtDNA expression and respiratory chain deficiency in midbrain DA neurons, which, in turn, leads to a parkinsonism phenotype with adult onset of slowly progressive impairment of motor function accompanied by formation of intraneuronal inclusions and dopamine nerve cell death. Confocal and electron microscopy show that the inclusions contain both mitochondrial protein and membrane components. These experiments demonstrate that respiratory chain dysfunction in DA neurons may be of pathophysiological importance in PD.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
MitoPark mice with conditional Tfam disruption in midbrain dopamine neurons develop respiratory chain deficiency, adult-onset progressive parkinsonism, intraneuronal inclusions, and dopamine neuron death. The findings provide genetic evidence that respiratory chain dysfunction in dopamine neurons may be pathophysiologically important in Parkinson’s disease.
Key findings
- MitoPark mice had reduced mtDNA expression in midbrain DA neurons at 6 weeks and marked reduction of COX enzyme activity at 20 weeks.
- Motor impairment began at ≈14–15 weeks, progressed to tremor, twitching, and apparent limb rigidity at ≈20 weeks, and mice were killed at ≈45 weeks; L-DOPA improved motor performance, with older mice showing abrupt termination resembling “wearing off.”
- DA innervation loss first appeared in dorsolateral striatum at 12 weeks; TH+ midbrain neuron loss was earlier and more marked in SN than VTA, and 20-week-old MitoPark mice had DA loss plus increased HVA/DA and DOPAC/DA ratios.
- Most midbrain DA neurons contained small cytoplasmic inclusions at 6 weeks before DA cell loss; inclusions contained mitochondrial protein and membrane components by confocal and electron microscopy, but did not contain α-synuclein and persisted in α-synuclein knockout MitoPark mice.
Methods
- Reverse genetic conditional knockout: DAT-cre mice were crossed with TfamloxP/TfamloxP mice to disrupt Tfam in midbrain DA neurons; cre expression was validated by in situ hybridization and reporter mice.
- Behavioral testing used automated activity cages for locomotion and rearing, with L-DOPA plus benserazide or PBS injections; histology, immunohistochemistry, in situ hybridization, electron microscopy, confocal microscopy, and HPLC catecholamine measurements were used.
- Sample sizes included 7 MitoPark/control pairs for in situ hybridization and enzyme histochemistry, 20 pairs for immunohistochemistry, 18 mice (9 littermate pairs) for TH cell counts, and 9 animals for aggregate counts and size measurements.
Limitations
- The paper states that the mechanism whereby respiratory chain deficiency leads to inclusion formation needs to be elucidated, that there was no evidence of α-synuclein in the inclusions, and that there is no absolute link between respiratory chain dysfunction and oxidative stress.
- The text makes evident that this is a mouse model rather than human PD, that the inclusions differ from human Lewy bodies in α-synuclein content, and that the h116–131 antibody reacted with an unknown inclusion component.
- The paper does not include a formal limitations section; additional limitations evident from the text include reliance on a single conditional knockout model and unresolved specificity of one α-synuclein antibody.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
25 Own result · 11 Own interpretation · 8 Not checked yet · 1 Own method · 1 No basis given
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In situ hybridizations detected much reduced expression of the mtDNA-encoded COX subunit I mRNA in DA neurons of substantia nigra (SN) and the ventral tegmental area (VTA) in MitoPark mice at the age of 6 weeks (Fig. 1E).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“accompanied by formation of intraneuronal inclusions and dopamine nerve cell death.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We also found a marked reduction of COX enzyme activity by histochemical analyses of midbrain DA neurons of 20-week-old MitoPark mice (Fig. 1D).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was no increased embryonic or neonatal lethality in MitoPark mice.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, five additional antibodies (see Methods) directed against α-synuclein were not immunoreactive with the inclusions although they gave rise to expected α-synuclein-like immunoreactivity in nonaffected neurons.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“accompanied by formation of intraneuronal inclusions and dopamine nerve cell death.”
- Also stated in: § Results · plain
“a majority of them contained small cytoplasmic aggregates (Fig. 4A–D).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found many examples where a mitochondrial marker protein, the nucleus-encoded α-subunit of mitochondrial ATP synthase, partially overlapped with, was juxtaposed to, or even surrounded the inclusions (Fig. 4 E and F).”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Decreased locomotion and reduced exploratory behavior first became apparent at age ≈14–15 weeks.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The absence of a functional α-synuclein gene had no obvious impact on the phenotype in MitoPark mice (data not shown).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Confocal and electron microscopy show that the inclusions contain both mitochondrial protein and membrane components.”
- Also stated in: § Results · hedged
“We found many examples where a mitochondrial marker protein, the nucleus-encoded α-subunit of mitochondrial ATP synthase, partially overlapped with, was juxtaposed to, or even surrounded the inclusions (Fig. 4 E and F).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · hedged
- It may state two separate claims as one. 13
- Probably not a substantial claim. 6
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Unexpectedly, the inclusions also remained, and were immunoreactive with the h116–131 antibody in the MitoPark mice lacking a functional α-synuclein gene (data not shown).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Quantification of numbers of tyrosine hydroxylase (TH)-expressing midbrain neurons revealed a slow progressive cell loss, which was more marked and had an earlier onset in SN, which predominantly innervates dorsal striatum, in comparison with VTA, which predominantly innervates ventral striatum and cortical areas (Fig. 3 E–I).”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Loss of DA innervation was first observed in dorsolateral striatum at age 12 weeks and this loss progressed to involve most of the dorsal and ventral striatum as the MitoPark mice became older (Fig. 3A–D).”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The inclusions were present in most midbrain DA neurons (Fig. 4C) and their mean size increased as neurodegeneration progressed (Fig. 4D).”
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Some of these bodies had an amorphous content and a diffuse lining, whereas others displayed tubular formations and were surrounded by distinct double layer membranes (Fig. 5 B and C).”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In 6-week-old MitoPark mice, there was no observable DA cell loss (Fig. 3F) despite the presence of severely reduced mtDNA expression (Fig. 1E) in midbrain DA neurons.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus α-synuclein was neither needed for the PD phenotype nor the development of DA neuron inclusions in our mice.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: α-synuclein is commonly found in Lewy bodies in human PD.
In the paper
“Available data show that Lewy bodies can have a variety of morphological shapes (25), and it has been suggested that their morphology evolves with time (25).”
What the sources say
- Not checked yetcites [25] Shults CW. Proc Natl Acad Sci USA. 2006;103:1661–1668. doi: 10.1073/pnas.0509567103. [DOI] [PMC free article] [PubMed] [Google Scholar]
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The morphology of Lewy bodies has mainly been studied in brain tissue obtained from end-stage PD patients, and it is therefore not well established how these aggregates appear at early disease stages.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“We used in situ hybridizations (Fig. 1B) and mating to reporter mice (23), which activate the expression of β-galactosidase in cre-expressing cells (Fig. 1C), to establish that DAT-cre mice express cre mRNA and enzymatically active cre-recombinase protein in DA neurons of the midbrain.”
What the sources say
- Not checked yetcites [23] Soriano P. Nat Genet. 1999;21:70–71. doi: 10.1038/5007. [DOI] [PubMed] [Google Scholar]
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This differential degeneration is also characteristic of PD in man.”
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper may give no reason why it holds.
In the paper
“It has recently been demonstrated that midbrain DA neurons of PD patients and elderly humans contain high levels of somatic mtDNA mutations, which may impair respiratory chain function.”
- Also stated in: § Abstract · boosted
“Analysis of mtDNA mutation levels in DA neurons with normal COX activity has demonstrated very high levels of mtDNA with deletions in both PD patients and aged controls and there was a linear increase of the mutation load with increasing age (7).”
What the sources say
- Not checked yetcites [7] Bender A, Krishnan KJ, Morris CM, Taylor GA, Reeve AK, Perry RH, Jaros E, Hersheson JS, Betts J, Klopstock T, et al. Nat Genet. 2006;38:515–517. doi: 10.1038/ng1769. [DOI] [PubMed] [Google Scholar] source
boostedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Abstract · boosted
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We demonstrate that respiratory chain deficiency in DA neurons in mice leads to characteristic manifestations of parkinsonism, including slowly progressive neuronal degeneration, typical behavioral disturbances, and the formation of intraneuronal inclusions.”
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In vitro studies have shown that α-synuclein can interact directly with lipids found in membranes (26, 27) and with proteins of the mitochondrial respiratory chain (28, 29).”
What the sources say
- Not checked yetcites [26] Cole NB, Murphy DD, Grider T, Rueter S, Brasaemle D, Nussbaum RL. J Biol Chem. 2002;277:6344–6352. doi: 10.1074/jbc.M108414200. [DOI] [PubMed] [Google Scholar]
- Not checked yetcites [27] Ellis CE, Murphy EJ, Mitchell DC, Golovko MY, Scaglia F, Barcelo-Coblijn GC, Nussbaum RL. Mol Cell Biol. 2005;25:10190–10201. doi: 10.1128/MCB.25.22.10190-10201.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Not checked yetcites [28] Hashimoto M, Takeda A, Hsu LJ, Takenouchi T, Masliah E. J Biol Chem. 1999;274:28849–28852. doi: 10.1074/jbc.274.41.28849. [DOI] [PubMed] [Google Scholar]
- Not checked yetcites [29] Elkon H, Don J, Melamed E, Ziv I, Shirvan A, Offen D. J Mol Neurosci. 2002;18:229–238. doi: 10.1385/JMN:18:3:229. [DOI] [PubMed] [Google Scholar]
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“TH-immunoreactive DA nerve cell body profiles were counted on coded slides at representative levels of SN and VTA, respectively, using two to five sections per animal and a total of 18 mice (nine littermate pairs, each consisting of one MitoPark and one control).”
plainn = 18- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“The mitochondrial network has an elaborate system for protein degradation involving membrane bound AAA-proteases and LON protease in the matrix (31).”
What the sources say
- Not checked yetcites [31] Rugarli EI, Langer T. Trends Mol Med. 2006;12:262–269. doi: 10.1016/j.molmed.2006.04.002. [DOI] [PubMed] [Google Scholar]
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
The paper relies on this without support.
Clinical studies have not established whether respiratory chain deficiency is a primary abnormality leading to inclusion formation and DA neuron death, or whether generalized metabolic abnormalities within degenerating DA neurons cause secondary damage to mitochondria.
“However, clinical studies have not established whether the respiratory chain deficiency is a primary abnormality leading to inclusion formation and DA neuron death, or whether generalized metabolic abnormalities within the degenerating DA neurons cause secondary damage to mitochondria.”
The paper relies on this without support.
α-synuclein is commonly found in Lewy bodies in human PD.
“However, we did not find evidence of α-synuclein in these inclusions, although α-synuclein is commonly found in Lewy bodies in human PD.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For all the targeted cell types, TFAM depletion leads to mtDNA depletion (not reported for midbrain DA neurons), mitochondrial transcript depletion (not reported for midbrain DA neurons) and respiratory chain deficiency, suggesting that TFAM is essential for mtDNA maintenance in vivo”
From Role of the mitochondrial DNA replication machinery in mitochondrial DNA mutagenesis, aging and age-related diseases (2017) · cites this paper as Ekstrand et al., 2007
In the citing paper
“TFAM deletion in mouse pyramidal neurons causes mitochondrial late-onset neurodegeneration (MILON) (Sorensen et al., 2001) whereas deletion in mouse midbrain DA neurons leads to PD (Ekstrand et al., 2007).”
From Role of the mitochondrial DNA replication machinery in mitochondrial DNA mutagenesis, aging and age-related diseases (2017) · cites this paper as Ekstrand et al., 2007
In the citing paper
“Alternative and more successful approaches to developing mouse models of mitochondrial disease involve manipulating the nuclear genes that regulate mtDNA maintenance and replication, such as TFAM [176][177][178][179][180][181][182], POLG ('Mutator' model) [183], and PEO1 (Twinkle; 'Deletor' model) [184].”
From Mitochondrial DNA mutations and human disease (2010) · cites this paper as [177]
Citations
Cites
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Generalized lacZ expression with the ROSA26 Cre reporter strain
Soriano, P. (1999) · Nature Genetics · doi:10.1038/5007 · Cited by 5,237
Premature ageing in mice expressing defective mitochondrial DNA polymerase
Trifunovic, A., Wredenberg, A., Falkenberg, M., Spelbrink, J. N., Rovio, A. T., Bruder, C. E., Bohlooly-Y, M., Gidlöf, S., Oldfors, A., Wibom, R., et al. (2004) · Nature · doi:10.1038/nature02517 · Cited by 2,734
Self-citationDrosophila pink1 is required for mitochondrial function and interacts genetically with parkin
Clark, I. E., Dodson, M. W., Jiang, C., Cao, J. H., Huh, J. R., Seol, J. H., Yoo, S. J., Hay, B. A., & Guo, M. (2006) · Nature · doi:10.1038/nature04779 · Cited by 1,788
Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin
Park, J., Lee, S. B., Lee, S., Kim, Y., Song, S., Kim, S., Bae, E., Kim, J., Shong, M., Kim, J.-M., et al. (2006) · Nature · doi:10.1038/nature04788 · Cited by 1,705
Mitochondrial transcription factor A is necessary for mtDNA maintance and embryogenesis in mice
Larsson, N.-G., Wang, J., Wilhelmsson, H., Oldfors, A., Rustin, P., Lewandoski, M., Barsh, G. S., & Clayton, D. A. (1998) · Nature Genetics · doi:10.1038/ng0398-231 · Cited by 1,594
Self-citationBender, A., Krishnan, K. J., Morris, C. M., Taylor, G. A., Reeve, A. K., Perry, R. H., Jaros, E., Hersheson, J. S., Betts, J., Klopstock, T., et al. (2006) · Nature Genetics · doi:10.1038/ng1769 · Cited by 1,570
Mitochondrial transcription factor A regulates mtDNA copy number in mammals
Ekstrand, M. I. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh109 · Cited by 919
Self-citationVolkow, N. D., Wang, G.-J., Fowler, J. S., Gatley, S. J., Logan, J., Ding, Y.-S., Hitzemann, R., & Pappas, N. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.10.1325 · Cited by 885
Cabin, D. E., Shimazu, K., Murphy, D., Cole, N. B., Gottschalk, W., McIlwain, K. L., Orrison, B., Chen, A., Ellis, C. E., Paylor, R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-20-08797.2002 · Cited by 865
Research works printed but not linked: 1
- H Andersson, J Luthman, E Lindqvist, L Olson Neurotoxicology 16, 201–210 (1995).
Cited by
Sorted by citations
Items 501–600 of 603
Ellioff, K. J., Osting, S., Lentine, A., Welper, A. D., Bürger, C., & Greenspan, D. S. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.01.567409 · Cited by 3
“At early time points, fragmented and swollen, spherical mitochondria were found in the SNc of Rcc1l KO / KO / Cre + mice, similar to the swollen, spherical mitochondria previously found in the DA neurons of DA neuron-specific Mfn2 -null mice (Lee et al., 2012; Pham et al., 2012), and in contrast to the diffuse weblike…”
InfluentialLee, Y. M., Hu, D., & Liou, Y. (2021) · Springer eBooks · doi:10.1007/978-981-16-0522-2_5 · Cited by 1
Pogorelov, V. M., Martini, M. L., Jin, J. J., et al. (2023) · Biomolecules · doi:10.3390/biom13111658 · Cited by 1
Drumond‐Bock, A. L., & Beckstead, M. J. (2025) · European Journal of Neuroscience · doi:10.1111/ejn.70025 · Cited by 1
“To accomplish this, the authors used the phenotypically-faithful MitoPark mouse model of PD, which is a dopamine neuron-specific knockout of mitochondrial transcription factor A (Tfam) (Ekstrand et al. 2007).”
Hu, C.-L., Lu, G.-Y., Kang, P.-L., Li, C.-J., Lin, M., Li, G.-L., & Su, F.-Y. (2025) · IEEE Access · doi:10.1109/access.2025.3569186 · Cited by 1
Parallel Gene Expression Changes in Ventral Midbrain Dopamine and GABA Neurons during Normal Aging
Drumond‐Bock, A. L., Blankenship, H. E., Pham, K. D., Carter, K. A., Freeman, W. M., & Beckstead, M. J. (2025) · eNeuro · doi:10.1523/eneuro.0107-25.2025 · Cited by 3
Zampese, E., Moran, J., & Surmeier, D. J. (2025) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-443-29867-7.00039-6 · Cited by 1
Microbial Metabolism of Levodopa as an Adjunct Therapeutic Target in Parkinson’s Disease
Feix, J. B., Cheng, G., Hardy, M., & Kalyanaraman, B. (2026) · Antioxidants · doi:10.3390/antiox15010120 · Cited by 2
“In addition, a transgenic (‘MitoPark’) mouse model, generated by selectively knocking out mitochondrial transcription factor A in dopaminergic neurons, recapitulates many of the clinical features of PD including neuronal loss and progressive motor dysfunction [13].”
Kuenstling, M. V., Szlachetka, A. M., & Mosley, R. L. (2013) · Springer protocols handbooks/Springer protocols · doi:10.1007/978-1-4614-8794-4_34 · Cited by 1
Molecular Pathogenesis and Pathophysiology of Parkinson’s Disease: New Targets for New Therapies
Castaño, J. G., González, C., Obeso, J. A., & Rodrı́guez, M. (2013) · Royal Society of Chemistry eBooks · doi:10.1039/9781849737357-00026 · Cited by 1
Mitochondrial Therapeutic Approaches in Parkinson’s Disease
Esteves, A. R., Silva, D. F., G-Fernandes, M., Gomes, R., & Cardoso, S. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-42139-1_9 · Cited by 1
Heteroreceptor Complexes Implicated in Parkinson’s Disease
Borroto‐Escuela, D. O., Narváez, M., Navarro, G., Franco, R., & Fuxé, K. (2017) · Springer eBooks · doi:10.1007/978-3-319-60174-8_20 · Cited by 1
AJ76 and UH232 as potential agents for diagnosing early-stage Parkinson's disease
Zhou, J., Li, J., Papaneri, A. B., & Cui, G. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109397 · Cited by 1
Animal Models of Mitochondrial Diseases Associated with Nuclear Gene Mutations
Averina, O. A., Kuznetsova, S. A., Permyakov, O. A., & Владимирович, С. П. (2024) · Acta Naturae · doi:10.32607/actanaturae.25442 · Cited by 2
Can We Accurately Model Mitochondrial Dysfunction in Neurodegeneration?
Aradjanski, M., & Trifunović, A. (2016) · Springer eBooks · doi:10.1007/978-3-319-28637-2_13 · Cited by 1
Self-citationDeterminants of Selective Vulnerability of Dopamine Neurons in Parkinson's Disease
Zampese, E., Galtieri, D. J., Schumacker, P. T., & Surmeier, D. J. (2016) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-12-802206-1.00041-6 · Cited by 2
Putative neuroprotective compounds in in vitro models of dopaminergic neurodegeneration
Ossola, B. (2011) · Työväentutkimus Vuosikirja · Cited by 1
Tetrahydroisoquinoline Neurotoxins in Parkinson Disease
DeCuypere, M. G. (2010) · doi:10.21007/etd.cghs.2010.0067 · Cited by 1
Genetic Models of Parkinson’s Disease
Palubinsky, A. M., Lizama, B. N., Miller, D. L., & McLaughlin, B. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800228-5.00014-5 · Cited by 1
Neuroprotection in Parkinson’s Disease
Jain, K. K. (2011) · Humana Press eBooks · doi:10.1007/978-1-61779-049-2_7 · Cited by 1
Radlicka-Borysewska, A., Jabłońska, J., Lenarczyk, M., Szumiec, Ł., Harda, Z., Bagińska, M., Pera, J., Kreiner, G., Wojcik, D. K., & Parkitna, J. M. R. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.23.525182 · Cited by 1
Xiao, X., Yeghiazaryan, G., Cremer, A. L., Backes, H., Kloppenburg, P., & Hausen, A. C. (2023) · eLife · doi:10.7554/elife.91716.1 · Cited by 1
Mitochondrial dysfunction Impairs the Nuclear Pore Complex in Parkinson’s Disease PathogenesisPreprint
Riaz, Z., Chang, Y.-T., Zenitsky, G. D., Jin, H., Anantharam, V., Kanthasamy, A., & Kanthasamy, A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.05.622143 · Cited by 1
Samidurai, M., Chennakesavan, K., Sarkar, S., Malovic, E., Nguyen, H. M., Singh, L., Kumar, A., Ealy, A., Janarthanam, C., Palanisamy, B. N., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.18.643982 · Cited by 1
“MitoPark mice were generated by Dr. Nils-Goran Larsson and colleagues at the Max Planck Institute for Biology of Ageing by conditionally knocking out TFAM in cells expressing the dopamine transporter (DAT), as described in Ekstrand et al. [86].”
Mitochondrial Involvement in Neurodegeneration and Aging
Pickrell, A. M. (2012)
The effects of mitochondrial DNA mutagenesis on somatic stem cells and ageing
Ahlqvist, K. J. (2015) · Työväentutkimus Vuosikirja
Manifestations of Drug Toxicity on Mitochondria in the Nervous System
Reynolds, I. J. (2008) · Wiley eBooks · doi:10.1002/9780470372531.ch8
The Role of Schwann Cell Mitochondrial Metabolism in Schwann Cell Biology and Axonal Survival
Viader, A. (2011) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7319sxj
Movement Disorders: Parkinson's Disease
Homayoun, H., & Goetz, C. G. (2014) · Methods and principles in medicinal chemistry · doi:10.1002/9783527679348.ch18
A D. melanogaster parkin mutant larval model of Parkinson's Disease
Vincent, A. (2013) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
The Pitx3-deficient aphakia mouse: a naturally occurring mouse model of dopamine deficiency
van den Munckhof, P. (2011) · UvA-DARE (University of Amsterdam)
Mitochondria in Parkinson's Disease
Arena, G., & Valente, E. M. (2015) · Wiley eBooks · doi:10.1002/9781119017127.ch16
Mitochondrial DNA mutations. Brain developmental and ageing consequences, and possible treatments
Ross, J. M. (2012) · Figshare
Neurodegenerative diseases studied in human brain and rodent models
Gellhaar, S. (2015) · Figshare
Association studies on susceptibility genes in Alzheimer disease
Björk, B. F. (2008) · Figshare
Understanding the Role of Sirtuin 3 in a Cell Model of Parkinson's Disease
Lizal, K. E. (2013) · TSpace (University of Toronto)
Cardiac and skeletal muscle adaptations in health and disease
Andersson, D. C. (2009)
LEVODOPAN AIHEUTTAMIEN DYSKINESIOIDEN NYKYISET JA KEHITTEILLÄ OLEVAT HOITOMUODOT
Nousiainen, S. (2016) · Työväentutkimus Vuosikirja
Glutamate Receptor Modulators as Emergent Therapeutic Agents in the Treatment of Parkinson’s Disease
Célanire, S., Perry, B., Lütjens, R., Poli, S. M., & Reynolds, I. J. (2013) · Royal Society of Chemistry eBooks · doi:10.1039/9781849737357-00237
The role of the foxa2 gene in the birth and death of dopamine neurons
Kittappa, R., Chang, W., & McKay, R. D. G. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374028-1.00034-8
Neurodegeneration in Mitochondrial Disorders
Phillips, J., Hayhurst, H., & Lax, N. Z. (2016) · Springer eBooks · doi:10.1007/978-3-319-28637-2_2
Misiak, M., & Arnold, S. (2010) · RWTH Publications (RWTH Aachen)
Degeneration mechanisms in human dopaminergic neurons
Pöltl, D. (2012) · KOPS (University of Konstanz)
Mehta, N. J. (2017) · Human Biology
GDNF and Neurturin isoforms in an experimental model of Parkinson's disease
Penttinen, A. (2017) · Työväentutkimus Vuosikirja
Manifestations of Drug Toxicity on Mitochondria in the Nervous System
Prehn, J. H. M., & Llorente‐Folch, I. (2018) · Wiley eBooks · doi:10.1002/9781119329725.ch9
Non-motor symptoms in Parkinson’s disease : modeling and mechanisms
Masini, D. (2018) · Figshare
Alternation of Mitochondrial and Golgi Apparatus in Neurodegenerative Disorders
Sharma, S., Kaur, P., Gupta, S., & Sharma, S. (2018) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-5225-5282-6.ch005
Characterization of Nonmotor Symptoms in the MitoPark Mouse Model of Parkinson’s DiseasePreprint
Langley, M. R., Ghaisas, S., Palanisamy, B. N., Ay, M., Jin, H., Anantharam, V., Kanthasamy, A., & Kanthasamy, A. G. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.02.365874
Model Cells and Organisms in Mitochondrial Diseases
Stefanatos, R. K. A., Sanz, A., & Fernández‐Ayala, D. J. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-70147-5_10
Kornmann, B. (2014) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.2111956.793490538
Hekimi, S., & Noë, A. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737301604.793572143
Brain Poster Session: Neurologic Disease
(2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.144
Krishnan, Y., & Saminathan, A. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734317494.793570817
Kazlauskas, A., & Jacobo, S. M. P. (2011) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.7404956.7796088
Assessment of Dopaminergic Neurodegeneration in Mice
Geertsma, H. M., Ricke, K. M., & Rousseaux, M. W. C. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2409-8_10
Animal Models and the Pathogenesis of Parkinson's Disease
Castaño, J. G., Iglesias, T., & de Yébenes, J. G. (2011) · Royal Society of Chemistry eBooks · doi:10.1039/bk9781849731843-00113
Animal Models of Parkinson's Disease
Rideout, H. J., & Stefanis, L. (2011) · Royal Society of Chemistry eBooks · doi:10.1039/bk9781849731843-00086
Xiao, X., Yeghiazaryan, G., Eggersmann, F. R., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.06.552140
(2023) · The MIT Press eBooks · doi:10.7551/mitpress/14411.003.0010
A Drosophila model of mitochondrial disease phenotypic heterogeneityPreprint
Granat, L., Knorr, D. Y., Ranson, D. C., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.05.570102
Muniyasamy, M., Durairaj, R., Usharani, B., Deivasigamani, A., & Chandrasekar, S. (2023) · Journal Of Advanced Zoology · doi:10.17762/jaz.v44is6.2613
Sterol Biomarker Discovery In Neurodegenerative Diseases
Pacciarini, M. (2023) · Cronfa (Swansea University) · doi:10.23889/suthesis.65375
Calcium Homeostasis in Dopaminergic Neurons
Frank, A. K., Boumhaouad, S., Fanourakis, S., Sulzer, D., & Mosharov, E. V. (2024) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780190932183.013.15
Mitochondrial Transplantation as a Newer Therapeutic Approach for Neurodegenerative Diseases
Kamalakannan, K., Bhupathyraaj, M., & Vijayarani, K. R. (2024) · Springer eBooks · doi:10.1007/978-981-19-3949-5_39-1
Causes and Consequences of Perturbations of the Mitochondrial Genome
King, D. E., Copeland, W. C., Wallace, K. B., & Meyer, J. N. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00128-5
Xiao, X., Yeghiazaryan, G., Eggersmann, F. R., Cremer, A. L., Backes, H., Kloppenburg, P., & Hausen, A. C. (2024) · eLife · doi:10.7554/elife.91716.2
Mitochondrial Transplantation as a Newer Therapeutic Approach for Neurodegenerative Diseases
Kamalakannan, K., Bhupathyraaj, M., & Vijayarani, K. R. (2024) · Springer eBooks · doi:10.1007/978-981-99-7557-0_39
PINK1-Parkin quality control mitophagy pathway in Parkinson’s disease
Thayer, J. A., & Narendra, D. P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15260-3.00013-2
The MitoPark mouse model of Parkinson's disease
Yasser, N., Haggag, A., Ahmed, N. A., Mohamed, B. S., Kumar, J., & Mohamed, H. H. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-16128-5.00010-4
Xiao, X., Yeghiazaryan, G., Eggersmann, F. R., Cremer, A. L., Backes, H., Kloppenburg, P., & Hausen, A. C. (2025) · eLife · doi:10.7554/elife.91716.3
Subsecond Analysis of Locomotor Activity in Parkinsonian Mice
Berezhnoi, D., Chehade, H. D., Simms, G., Chen, L., Narasimhan, K., Dravid, S., & Chu, H.-Y. (2024) · eNeuro · doi:10.1523/eneuro.0014-25.2025
“2 A ; Ekstrand et al., 2007; Galter et al., 2010; Panigrahi et al., 2015; Beckstead and Howell, 2021).”
InfluentialA molecular atlas of cell-type specific signatures in the parkinsonian striatumPreprint
Graziano, M., Mantas, I., Masarapu, Y., Frapard, S., Garza, R., Adami, A., Fazal, S. V., Quaegebeur, A., Barker, R. A., Jakobsson, J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.09.675138
“The latter function is particularly relevant to our study, as the MitoPark model is based on mitochondrial deficits restricted to DAergic neurons 12 .”
InfluentialRodent models for exploring the mechanisms contributing to Parkinson's disease pathophysiology
Allison, J., & Duty, S. (2025) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-443-21992-4.00003-8
Wang, V., Tseng, K.-Y., Kuo, T.-T., Huang, E. Y., Lan, K.-L., Chen, Z.-R., Ma, K.-H., Greig, N. H., Jung, J. H., Choi, H.-I., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26707895
Self-citationGhosh, A. (2012) · Iowa State University Digital Repository (Iowa State University) · doi:10.31274/etd-180810-1769
Meshul, C. K., Moore, C., Shin, K., Sandhu, N. K., Lee, J. S., Zhao, A., & D’Silva, T. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29090-9.00017-9
Kuo, C.-W., Nguyen, T. X. D., Chen, K., Liu, H.-L., Wu, C.-K., Peng, C., Chang, M., & Hsieh, T.-H. (2026) · Journal of Integrative Neuroscience · doi:10.31083/jin48187
“These mice exhibit motor deficits between 14 and 20 weeks of age, gradual nigrostriatal dysfunction, and responsiveness to treatments, closely mimicking the clinical features of human PD [15– 17].”
Sargent, D. (2018) · theses.fr (ABES) · doi:10.70675/2cd4ead6z0cd7z476dz8376z54bb3bd9a0ea
Spatio-temporal contribution of Dopamine in the execution of Goal-directed movement in rats
Gauthier, S. (2022) · theses.fr (ABES) · doi:10.70675/2e9049f3z7a59z4660z8820z667ebc97130e
Impacts de la modulation du cholestérol cérébral dans la maladie de Parkinson
Rousselot, L. (2023) · theses.fr (ABES) · doi:10.70675/c92a8ee9zd623z4ebbz813az17685082f328
Zhang, X., Jiang, F., Ling, C., Liu, F., Feng, Z., Wu, N., & Zhu, Y. (2026) · Neuropharmacology and Therapy · doi:10.15212/npt-2025-0022
Do animal models represent the diversity of clinical Parkinson’s disease?
Cenere, M. M., Schirinzi, T., Ledonne, A., & Mercuri, N. B. (2026) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2026.103220
The role of energy deficit in autophagy failure in Parkinson’s disease
Bosnjak, M., Misirkic-Marjanovic, M., Kosic, M., Mandic, M., Vučićević, L., Paunović, V., & Harhaji-Trajkovic, L. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1846307 · Cited by 2
“…(MPP ), and rotenone inhibit mitochondrial complex I in vitro and in vivo, while genetic models such as MitoPark mice recapitulate progressive parkinsonism due to selective mitochondrial respiratory chain deficiency (Smeyne and Jackson-Lewis, 2005; Xiong et al., 2012; Ekstrand et al., 2007).”
Bao-Sheng, W. A. N. G., & Ben, Z. H. O. U. (2026) · Shengming kexue · doi:10.3724/cbls.2026103
Locarno, A., Mantzafou, A., Ferraris, J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.16.737908
“DAT-Cre (70), DAT-tdTomato mice generated by crossing DAT-Cre mice with Ai14 reporter mice (B6.”
Akanchise, T., Luo, F., Angelov, B., Deng, Y., Fujino, T., & Angelova, A. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02897-w
Tseng, K.-Y., Kuo, T., Chang, P.-K., Chou, J.-L., Huang, E. Y., Greig, N. H., Choi, H.-I., Olson, L., Hoffer, B. J., & Chen, Y.-H. (2026) · Journal of Parkinson s Disease · doi:10.1177/1877718x261477621
Self-citationArias-Carrión, Ó., Guerra‐Crespo, M., Soto-Rojas, L. O., Valle, Y., Ortega‐Robles, E., & Ortuño‐Sahagún, D. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1886917 · Cited by 2
“…neuron–specific deletion of the mitochondrial transcription factor A (TFAM), which is essential for mtDNA transcription and replication, leads to progressive motor impairment, nigral neuron loss, and responsiveness to levodopa, mirroring key clinical features of PD (Ekstrand et al., 2007).”
Metadata
- Authors
- Ekstrand, M. I., Terzioglu, M., Galter, D., Zhu, S., Hofstetter, C., Lindqvist, E., Thams, S., Bergstrand, A., Hansson, F. S., Trifunovic, A., Hoffer, B., Cullheim, S., Mohammed, A. H., Olson, L., & Larsson, N.-G.
- Affiliations
- Karolinska University Hospital (SE)
- Department of Laboratory Medicine and
- Karolinska Institutet (SE)
- National Institutes of Health (US)
- Corresponding author
- Larsson, Nils-Göran
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2007-01-23
- Volume
- 104
- Issue
- 4
- Pages
- 1325-1330
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC1783140
- OpenAlex
- W2055557007
- Semantic Scholar
- eae41525f2f96b0fa42114d58d84dc3353e90137
- Cited by
- 605
- References
- 33
- Citations by year
- 2026: 20 · 2025: 25 · 2024: 35 · 2023: 32 · 2022: 25 · 2021: 33 · 2020: 40 · 2019: 34 · 2018: 38 · 2017: 28 · 2016: 19 · 2015: 32 · 2014: 31 · 2013: 32 · 2012: 29
- FWCI
- 23.38
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Michael J. Fox Foundation for Parkinson's Research
- Karolinska Institutet
- Vetenskapsrådet
- Swedish Brain Power
- National Institutes of Health
- U.S. Public Health Service
- Parkinsonfonden
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, mitochondrial dysfunction, respiratory chain deficiency, dopaminergic neurons, midbrain, Lewy bodies, TFAM, mitochondrial DNA mutations, conditional knockout mice, parkinsonism, motor impairment, intraneuronal inclusions
- MeSH terms
- Animals, Base Sequence, Dopamine, Electron Transport, Immunohistochemistry, Microscopy, Electron, Neurons, DNA Probes, In Situ Hybridization, Parkinsonian Disorders, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
